Cladribine Export Market Intelligence: India's 50 Suppliers Shipping to 29 Countries — TransData Nexus 2026

Q: Who are the top cladribine exporters from India?

The top cladribine exporters from India are: 1. RMPL PHARMA LLP — $37.3K (16.0% market share); 2. GNH INDIA PHARMACEUTICALS LIMITED — $12.5K (5.4% market share); 3. TRIKAYA GLOBAL — $12.0K (5.1% market share); 4. RIZLIFE HEALTHCARE — $10.7K (4.6% market share); 5. ATLAS ENTERPRISES — $8.6K (3.7% market share). Together they account for 34.9% of India's total cladribine export value.

Q: What is the total export value of cladribine from India?

The total export value of cladribine from India is $232.8K USD, recorded across 125 shipment transactions from 50 active exporters to 29 destination countries. The average shipment value is $1.9K.

Q: Which countries import cladribine from India?

India exports cladribine to 29 countries worldwide. The top importing countries are: LEBANON (21.2% share, $49.3K), MALAYSIA (15.9% share, $37.0K), SINGAPORE (8.6% share, $20.0K), UNITED ARAB EMIRATES (6.5% share, $15.2K), MEXICO (5.8% share, $13.6K). These five markets account for 58.1% of total export value.

Q: What is the HS code for cladribine exports from India?

The primary HS code for cladribine exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of cladribine exports from India?

The average unit price for cladribine exports from India is $116.50 USD per unit, with prices ranging from $0.40 to $221.99 depending on formulation, packaging, and order volume. The total market is valued at $232.8K across 125 shipments.

Q: Which ports handle cladribine exports from India?

The primary ports for cladribine exports from India are SAHAR AIR CARGO ACC (INBOM4) (27.2% of shipments), SAHAR AIR (25.6% of shipments), DELHI AIR CARGO ACC (INDEL4) (8.8% of shipments), Bombay Air Cargo (8.8% of shipments), Bombay Air (8.0% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of cladribine?

India is one of the world's leading exporters of cladribine due to its large base of 50 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports cladribine to 29 countries, demonstrating 15% global market coverage.

Q: What certifications do Indian cladribine exporters need?

Indian cladribine exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import cladribine from India?

There are 62 registered buyers importing cladribine from India, spread across 29 countries. The repeat buyer rate is 43.5%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top cladribine supplier from India?

RMPL PHARMA LLP is the leading cladribine exporter from India with a market share of 16.0% and total export value of $37.3K across 5 shipments. The top 5 suppliers together control 34.9% of total export value.

Suresh Sormare

Cladribine

India Pharmaceutical Trade Intelligence

$232.8K50 Suppliers29 CountriesHS 30049049

ExportsIndia → LEBANON21.2%India → MALAYSIA15.9%

ImportsITALY → India$4.5M UNITED STATES → India$1.3M

#1 Supplier: RMPL PHARMA

Cladribine Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Cladribine to the World

Between 2022 and 2026, India exported $232.8K worth of cladribine across 125 verified shipments to 29 countries — covering 15% of world markets in the Advanced Oncology segment. The largest destination is LEBANON (21.2%). RMPL PHARMA LLP leads with a 16.0% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30049049

Cladribine export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Cladribine export data snapshot — $232.8K · 50 exporters · 29 countriesTransData Nexus · Indian Customs Data

Top Cladribine Exporters from India

50 active exporters · Ranked by export value

View all 50 →

Top Cladribine Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	RMPL PHARMA LLP	$37.3K	5	1	16.0%
2	GNH INDIA PHARMACEUTICALS LIMITED

Top Countries Importing Cladribine from India

29 destination markets · Ranked by import value

All 29 countries →

Top Countries Importing Cladribine from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	LEBANON	$49.3K	21.2%
2	MALAYSIA	$37.0K	15.9%
3	SINGAPORE	$20.0K	8.6%
4	UNITED ARAB EMIRATES	$15.2K	6.5%
5	MEXICO	$13.6K	5.8%
6	VENEZUELA	$11.4K	4.9%
7	QATAR	$10.7K	4.6%
8	UNITED STATES	$9.4K	4.0%
9	OMAN	$8.5K	3.7%
10	BELIZE	$7.7K	3.3%

LEBANON is India's largest cladribine export destination, absorbing 21.2% of total exports worth $49.3K. The top 5 importing countries — LEBANON, MALAYSIA, SINGAPORE, UNITED ARAB EMIRATES, MEXICO — together account for 58.1% of India's total cladribine export value. The remaining 24 destination countries collectively receive the other 41.9%, indicating a focused distribution strategy targeting key markets.

Who Supplies Cladribine to India?

7 origin countries · Total import value: $7.3M

India imports cladribine from 7 countries with a combined import value of $7.3M. The largest supplier is ITALY ($4.5M, 2 shipments), followed by UNITED STATES and BELGIUM. All values are from Indian Customs (DGFT) import records.

Countries Supplying Cladribine to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	ITALY	$4.5M	2	62.1%
2	UNITED STATES	$1.3M	3	18.1%
3	BELGIUM	$823.6K	2	11.3%
4	CANADA	$373.6K	5	5.1%
5	NETHERLANDS	$243.9K	1	3.4%
6	JORDAN	$129	1	0.0%
7	GREECE	$30	1	0.0%

ITALY is the largest supplier of cladribine to India, accounting for 62.1% of total import value. The top 5 origin countries — ITALY, UNITED STATES, BELGIUM, CANADA, NETHERLANDS — together supply 100.0% of India's cladribine imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Cladribine

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, the U.S. Food and Drug Administration (FDA) has approved several Abbreviated New Drug Applications (ANDAs) for Cladribine. Notably, on March 22, 2023, Apotex Corp. received approval for ANDA 218425 for Cladribine Tablets, 10 mg, deemed bioequivalent to EMD Serono's Mavenclad Tablets, 10 mg. The reference listed drug, Mavenclad, is protected by patents expiring between May 31, 2026, and November 23, 2038.

The presence of 50 active Indian exporters indicates a competitive landscape for Cladribine exports to the U.S. market. However, the existing patent protections may limit the immediate market entry of generic versions. Importantly, there are no current FDA import alerts specific to Cladribine, suggesting compliance with U.S. regulatory standards.

2EU & UK Regulatory Framework

In the European Union, Cladribine is marketed under the brand name Mavenclad, authorized by the European Medicines Agency (EMA) on August 22, 2017, for the treatment of highly active relapsing multiple sclerosis. (ema.europa.eu) Additionally, Litak, another Cladribine-containing product, has been authorized since April 14, 2004, for the treatment of hairy-cell leukemia. (ema.europa.eu)

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA's approvals, ensuring that Cladribine products meet stringent EU Good Manufacturing Practice (GMP) requirements. These standards necessitate comprehensive quality assurance measures, including validation of manufacturing processes and rigorous quality control testing.

3WHO Essential Medicines & Global Standards

Cladribine is not listed in the World Health Organization's (WHO) Model List of Essential Medicines. Consequently, it has not undergone the WHO Prequalification Programme. However, Cladribine's inclusion in major pharmacopoeias such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) underscores its recognized therapeutic value and establishes standardized quality benchmarks for its production and quality control.

4India Regulatory Classification

In India, Cladribine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. As of March 2026, Cladribine is not listed under the Drug Price Control Order (DPCO) by the National Pharmaceutical Pricing Authority (NPPA), meaning it is not subject to government-mandated price ceilings. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

5Patent & Exclusivity Status

Cladribine's patent landscape is complex. In the U.S., key patents for Mavenclad are set to expire between May 31, 2026, and November 23, 2038. This extended patent protection period may delay the entry of generic competitors into the market. In the EU, similar patent protections are in place, affecting the market dynamics for generic Cladribine products.

6Recent Industry Developments

1. FDA Approval of Apotex's Generic Cladribine Tablets: In March 2023, the FDA approved Apotex Corp.'s ANDA for Cladribine Tablets, 10 mg, marking a significant development in the availability of generic Cladribine in the U.S. market.

2. EMA's Safety Update on Cladribine: In September 2017, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for Cladribine-containing products, highlighting the potential risk of Progressive Multifocal Leukoencephalopathy (PML). (ema.europa.eu)

3. WHO's Inclusion of Cladribine in Pharmacopoeias: As of March 2026, Cladribine continues to be included in major pharmacopoeias, including the USP, BP, EP, and IP, reflecting its established therapeutic use and standardized quality requirements.

These developments underscore the evolving regulatory and market landscape for Cladribine, highlighting the importance of ongoing compliance with international standards and vigilance regarding safety updates.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Cladribine

Retail & reference prices across 9 markets vs. India FOB export price of $116.50/unit

Global Price Benchmark for Cladribine across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$8,845.45	USD	According to the FDA-approved prescribing information, the recommended cumulative dose is 3.5 mg/kg over two years, with an average annual cost of approximately $43,158 for a 70 kg patient.
United Kingdom	Approximately $2,373	GBP	Cladribine is listed in the UK's National Health Service (NHS) Drug Tariff, indicating its availability and reimbursement status within the NHS framework.
Germany	Approximately $2,373	EUR	Cladribine is regulated by the European Medicines Agency (EMA) and is included in Germany's healthcare system, with pricing subject to negotiations between manufacturers and statutory health insurance funds.

Supply Chain Risk Assessment — Cladribine

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Cladribine, an antineoplastic agent, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used for U.S.-approved APIs are solely sourced from China, as reported by the U.S. Pharmacopeia in October 2025. Such reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have underscored these vulnerabilities. In March 2026, the closure of the Strait of Hormuz, a critical maritime passage, led to significant delays in the shipment of raw materials, including those essential for pharmaceutical manufacturing. This event highlighted the fragility of supply chains dependent on specific geographic regions for critical inputs.

2Supplier Concentration & Single-Source Risk

The export market for Cladribine from India is characterized by a moderate level of supplier concentration. The top five exporters account for 34.9% of the total export value, with RMPL Pharma LLP leading at a 16.0% share. This distribution suggests a relatively diversified supplier base, which can mitigate risks associated with over-reliance on a single exporter.

To further reduce dependency on specific suppliers and enhance supply chain resilience, the Indian government has implemented the Production Linked Incentive (PLI) scheme. This initiative aims to bolster domestic manufacturing of APIs and KSMs, thereby decreasing reliance on imports and promoting a more robust pharmaceutical supply chain.

Access Complete Cladribine Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 125 transactions across 29 markets.

Request Demo View Pricing

Frequently Asked Questions — Cladribine Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top cladribine exporters from India?

The leading cladribine exporters from India are RMPL PHARMA LLP, GNH INDIA PHARMACEUTICALS LIMITED, TRIKAYA GLOBAL, and 7 others. RMPL PHARMA LLP leads with 16.0% market share ($37.3K). The top 5 suppliers together control 34.9% of total export value.

What is the total export value of cladribine from India?

The total export value of cladribine from India is $232.8K, recorded across 125 shipments from 50 active exporters to 29 countries. The average shipment value is $1.9K.

Which countries import cladribine from India?

India exports cladribine to 29 countries. The top importing countries are LEBANON (21.2%), MALAYSIA (15.9%), SINGAPORE (8.6%), UNITED ARAB EMIRATES (6.5%), MEXICO (5.8%), which together account for 58.1% of total export value.

What is the HS code for cladribine exports from India?

The primary HS code for cladribine exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Cladribine

Cladribine

Top Cladribine Exporters from India

Top Countries Importing Cladribine from India

Who Supplies Cladribine to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Cladribine

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Cladribine

Supply Chain Risk Assessment — Cladribine

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Cladribine Trade Intelligence

Frequently Asked Questions — Cladribine Exports from India

Who are the top cladribine exporters from India?

What is the total export value of cladribine from India?

Which countries import cladribine from India?

What is the HS code for cladribine exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of cladribine exports from India?

Which ports handle cladribine exports from India?

Why is India a leading exporter of cladribine?

What certifications do Indian cladribine exporters need?

How many buyers import cladribine from India?

What is the market share of the top cladribine exporter from India?

Analysis Methodology